MORRISTOWN, N.J., March 09, 2023 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will be participating in investor meetings at the Barclays Global Healthcare Conference at the Loews Miami Beach Hotel on March 14, 2023.
Meeting Details
For investors attending the conference who wish to meet with the Intercept management team, please reach out to Nareg Sagherian at Intercept to check the team’s availability.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH) and severe alcohol-associated hepatitis (sAH). For more information, please visit www.interceptpharma.com or connect with the Company on Twitter and LinkedIn.
Contact
For more information about Intercept, please contact:
Investor inquiries: investors@interceptpharma.com
Media inquiries: media@interceptpharma.com
HONOLULU, Hawaii, April 05, 2025 (GLOBE NEWSWIRE) -- Arialief is nutritional support specifically designed to…
CHICAGO, April 4, 2025 /PRNewswire/ -- In a historic moment, BlackDoctor.org (BDO) inducts its first…
PHILADELPHIA--(BUSINESS WIRE)--#EAP--Vital Start Health is now offering direct access to its virtual reality programs and…
MARLBOROUGH, Mass.--(BUSINESS WIRE)--$HOLX #governance--Hologic, Inc. (Nasdaq: HOLX) announced today that Wayde McMillan has been elected…
NEWTOWN, Pa., April 4, 2025 /PRNewswire/ -- Edelson Lechtzin LLP, a national class action law…
AVON, Conn., April 4, 2025 /PRNewswire/ -- Constitution Billing and Financial Services (CBFS), a subsidiary of…